Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Liabilities and Shareholders Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Liabilities and Shareholders Equity for 15 consecutive years, with $9.7 million as the latest value for Q3 2025.

  • Quarterly Liabilities and Shareholders Equity fell 6.04% to $9.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $35.5 million through Sep 2025, down 15.7% year-over-year, with the annual reading at $8.7 million for FY2025, 11.66% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $9.7 million at IGC Pharma, up from $7.9 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $35.9 million in Q1 2021, with the low at $7.9 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $18.7 million, with a median of $16.5 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity rose 29.49% in 2021, then crashed 43.9% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $31.3 million in 2021, then tumbled by 35.85% to $20.1 million in 2022, then plummeted by 43.9% to $11.3 million in 2023, then dropped by 19.37% to $9.1 million in 2024, then grew by 7.33% to $9.7 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $9.7 million, $7.9 million, and $8.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.